Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to better characterize the fluctuations in multiple sclerosis symptoms and their relationship to medications, to length/extent of disease, and to a variety of physiologic measures.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Relapsing Remitting Multiple Sclerosis | Those who document during the study on-boarding process that they suffer from relapsing-remitting multiple sclerosis. |
| |
| Primary Progressive Multiple Sclerosis | This who document during the on-boarding process that they suffer from primary progressive multiple sclerosis. |
| |
| Secondary Progressive Multiple Sclerosis | This who document during the on-boarding process that they suffer from secondary progressive multiple sclerosis. |
| |
| Control | This who document during the on-boarding process that they do not suffer from multiple sclerosis. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Personal history of multiple sclerosis | Other | Participants will be stratified into one of four cohorts based on their experience (or lack of experience) with the three major forms of multiple sclerosis. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in perceived fatigue severity (self-report) as recorded by symptom diary | Every 24 hours through study completion, an average of 6 months | |
| Change in perceived cognitive impairment (self-report) as recorded by symptom diary | Severity of cognitive impairment experienced from multiple sclerosis | Every 24 hours through study completion, an average of 6 months |
| Change in perceived depression or anxiety severity (self-report) as recorded by symptom diary | Severity of any mood disorders experienced from multiple sclerosis | Every 24 hours through study completion, an average of 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change in perceived walking instability (self-report) as recorded by symptom diary | Every 24 hours through study completion, an average of 6 months | |
| Change in perceived vision difficulties (self-report) as recorded by symptom diary | Every 24 hours through study completion, an average of 6 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Study subjects will be self-selecting from the national release of a mobile application.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Fletcher L Hartsell, MD MPH | Duke University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Duke University Medical Center | Durham | North Carolina | 27710 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Change in perceived Bowel/Bladder dysfunction (self-report) as recorded by symptom diary | Severity of bowel/bladder dysfunction experienced from multiple sclerosis | Every 24 hours through study completion, an average of 6 months |
| Change in perceived sensory disturbance (self-report) as recorded by symptom diary | Every 24 hours through study completion, an average of 6 months |
| Change in perceived vertigo severity (self-report) as recorded by symptom diary | Every 24 hours through study completion, an average of 6 months |
| Change in perceived dysarthria severity (self-report) as recorded by symptom diary | Every 24 hours through study completion, an average of 6 months |
| Change in pain (self-report) as recorded by symptom diary | Every 24 hours through study completion, an average of 6 months |
| Change in sleep quality as recorded by app-linked wearable device | Every 24 hours through study completion, an average of 6 months |
| Change in medication adherence (self-report) as recorded by medication diary | Every 24 hours through study completion, an average of 6 months |
| Change in self-efficacy (self-report) as determined by the Multiple Sclerosis self-efficacy scale (survey instrument) | every three months, through study completion (an average of 6 months) |
| Change in Multiple Sclerosis Quality of Life Inventory | The Multiple Sclerosis Quality of Life Inventory surveys are prompted based on the app user's responses on the daily surveys. | prompted based on the app user's responses on the daily surveys, up to 6 months |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |